ONC 782
Alternative Names: ONC-782Latest Information Update: 04 Dec 2024
Price :
$50 *
At a glance
- Originator OncoC4
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunoconjugates
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 25 Sep 2024 Preclinical trials in Haematological malignancies in USA (Parenteral), prior to September 2024
- 25 Sep 2024 Preclinical trials in Solid tumours in USA (Parenteral), prior to September 2024
- 25 Sep 2024 OncoC4 plans a phase I investigator-initiated trial for ONC 782 in China in the second half of 2024